Alzheimer's drug Leqembi Expected to be Approved by the US FDA

Abstract:

Leqembi (Lecanemab), a new drug for Alzheimer's disease jointly developed by Eisai of Japan and Biogen of the United States, will become the first new drug for Alzheimer's disease to be fully approved by the FDA in 20 years. On June 9, local time, the US Food and Drug Administration (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (hereinafter referred to as the "FDA Advisory Committee") fully approve Leqembi. The FDA's final decision is expected on or before July 6.